WASHINGTON--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today announced findings from a preclinical study suggesting that C-20081, a novel, deuterium-containing oxazolidinone antibiotic, may be suitable for once-daily oral and intravenous dosing. In the preclinical study, C-20081 had a 43% increase in plasma half-life compared to linezolid, which might allow for lower overall drug exposure and improved tolerability with a once-daily dose. These findings were presented in a poster presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the 46th Annual Meeting of the Infectious Diseases Society of America (IDSA), a joint meeting being held in Washington, DC.
